E1A10 – A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients with Relapsed Waldenstrom’s Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom’s Macroglobulinemia (Phase II)
Physician and Research Staff Educational Materials:
These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.
- Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study intended for promotional use among health care professionals.
Additional Information at ClinicalTrials.gov: